Year: 2002
Type: article
Abstract: Adjuvant therapy for patients with melanoma using interferon α remains controversial despite numerous randomized clinical trials. In the current study, Kirkwood et al. present the results of a biologic companion trial to Intergroup Trial E1690, which compared high‐dose and low‐dose interferon α2b with observation after surgery. The implications for current practice and future clinical trials are discussed. See also pages 1102‐12.
Source: Cancer
DOI: 10.1002/cncr.10779
Author: Vernon K. Sondak
Institutions: University of Michigan, U-M Rogel Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W1980649416